Loss of Response of Adalimumab Biosimilar Compared With the Loss of Response of Adalimumab Original: Controlled, Randomized, Non-inferiority Open Study. "ADA-SWITCH Study"
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Change from baseline to final follow-up in the response of the switch.
研究概览
简要总结
Loss of response of the Adalimumab biosimilar compared with the original drug.
详细描述
A single-site Unicentric, randomized, parallel-group, non-inferiority open study including patients diagnosed with inflammatory bowel disease (Crohn's disease and Ulcerative Colitis) who were in clinical remission with Adalimumab original for at least 6 months prior to the start of the study.
A total of 216 patients with inflammatory bowel disease from the Inflammatory Unit of the Virgin Macarena University Hospital will be randomized 1:1 to receive the study drug, Adalimumab biosimilar (AMGEVITA®) subcutaneous 40mg every 15 days or maintain the original drug (Humira®) 40 mg subcutaneous every 15 days.
The dosage of the medication will be administrated according to the product's approved label by SmPC (Summary of Product's Characteristics)by technical file. Administration will be accepted every 7 days, if the patient after inclusion criteria is included with intensified dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be male or female over 18 years of age
- •Be a Patient with a previous confirmed diagnosis of Crohn´s disease an Ulcerative Colitis
- •Previous treated with original Adalimumab for at least 6 months with regular maintenance dose (40 mg every 15 days) and in clinical and biological remission.
- •Patients under treatment with intensified Adalimumab (40mg every 7 days or 80mg every 7 days) to maintain clinical and biological remission for at least 6 months.
- •Patients with oral mesalazine with a stable dose for more than 30 days.
- •Patients with immunosuppressive therapy (methotrexate, azathioprine) with a minimum intake time> 60 days.
- •Patients may be accepted with corticosteroids at the established doses:
- •prednisone <20mg / dl, budesonide <9mg / dl.
- •Patients who have a tuberculosis (TB) study (Mantoux / QuantiFERONTB test) updated in the last two year, with a negative result.
- •Patient with serology hepatitis B and C, updated at the beginning of the treatment with Humira®
- •Sign an informed consent document indicating that he/she understands the purpose of, and procedures required for, the study and are willing to participate in the study.
排除标准
- •Positive pregnancy test at the time of inclusion or during the follow-up period, as well as women who are breastfeeding
- •Patients with uncontrolled comorbidities, active cancer, diabetes mellitus, severe cardiovascular disease, obstructive pulmonary disease, serious active infections.
- •Patients with oral mesalazine initiated less than 30 days.
- •Patients with immunosuppressive therapy (methotrexate, azathioprine) with a minimum intake time of <60 days.
- •Patient with original Adalimumab who do not meet a minimum of 6 months of stable dose (40 mg every 7 or 15 days)
- •Patient on corticosteroid therapy at doses: prednisone> 20mg / dl, budesonide = 9mg / dl, or with IV corticoids within 14 days prior screening date.
- •Patients with mental disorders, alcohol / other substance abuse, or conditions that do not allow adherence to the study protocol.
- •Patients with active TB
- •Patients with defined Hepatitis B and C defined as:
- •HBV: hepatitis B surface antigen (HbsAg) positive together with positive HBV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR). HCV: HCV ribonucleic acid (RNA) detectable in any patient with positive anti-HCV antibody (IgG)
研究组 & 干预措施
switch-cohort
Adalimumab biosimilar
干预措施: Amgevita 40Mg Solution for Injection (Drug)
non-switchcohort
Adalimumab original
干预措施: HUMIRA 40Mg Solution for Injection (Drug)
结局指标
主要结局
Change from baseline to final follow-up in the response of the switch.
时间窗: From date of randomization until the date of first documented change from baseline status in concomitant steroids needed or increment in dose or frequency of adalimumab biosimilar or urgent surgery indication ever came first, assessed up to 13 months
To assess if there is a change in the response of the switch (replacement) from Adalimumab original (Humira®) to Adalimumab biosimilar (Amgevita®) trhough the quantification of concomitant steroids needed or increment in dose or frequency of adalimumab biosimilar or urgent surgery indication
次要结局
- Surgery rate(0, 3, 6, 9, 12, 13 months)
- The score of the Visual Analogue Scale (VAS)(0, 3, 6, 9, 12, 13 months)
- Compare the antibody formation rate.(0, 3, 6, 9, 12, 13 months)
- The score of the specific quality of life questionnaire(0, 3, 6, 9, 12, 13 months)
- Maintenance of bioquimical remission trhough C-reactive protein(0, 3, 6, 9, 12, 13 months)
- Maintenance of bioquimical remission through Calprotectin values(0, 3, 6, 9, 12, 13 months)
- Drug levels(0, 3, 6, 9, 12, 13 months)
- Adverse Event(0, 3, 6, 9, 12, 13 months)
- Hospital admission rate(0, 3, 6, 9, 12, 13 months)